3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Primary Myelofibrosis
39
Myeloproliferative Disorders
30
Leukemia, Myeloid, Acute
23
Polycythemia Vera
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Leukemia
17
Myelodysplastic Syndromes
15
Thrombocythemia, Essential
12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Neoplasms
9
Multiple Myeloma
9
Graft vs Host Disease
9
Breast Neoplasms
9
Pancreatic Neoplasms
8
Leukemia, Myelomonocytic, Chronic
8
Recurrence
7
Myelodysplastic-Myeloproliferative Diseases
7
Lymphoma, Non-Hodgkin
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Hematologic Neoplasms
6
Prostatic Neoplasms
5
Lymphoma, T-Cell
5
Lymphoma
5
Leukemia, Myeloid, Chronic-Phase
5
Hodgkin Disease
5
Hematologic Diseases
5
Colorectal Neoplasms
5
Thrombocytosis
4
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
4
Carcinoma, Non-Small-Cell Lung
4
Interventions
Carboplatin
7
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Epirubicin
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Observation
2
Monatide (IMS 3015)
2
Metformin
2
Leucovorin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pathologic Complete Response
×
ruxolitinib
×
Clear all
NCT04934670
2024-08-27
2002
Xenikos
Phase 3
Terminated
12 enrolled
12 charts